|
| | Irsogladine Basic information |
| Product Name: | Irsogladine | | Synonyms: | 5-triazine-2,4-diamine,6-(2,5-dichlorophenyl)-3;6-(2,5-dichlorophenyl)-1,3,5-triazine-2,4-diamine;2,4-diamino-6-(2,5-dichlorophenyl)-1,3,5-triazine;Irsogladin;Irsogladine,2,4-DiaMino-6-(2,5-dichlorophenyl)-1,3,5-triazine;IRSOGLADINE;Irsogladine free base;2',5'-Dichlorobenzoguanamine | | CAS: | 57381-26-7 | | MF: | C9H7Cl2N5 | | MW: | 256.09 | | EINECS: | | | Product Categories: | Active Pharmaceutical Ingredients;pharmaceutical intermediates;Inhibitors | | Mol File: | 57381-26-7.mol |  |
| | Irsogladine Chemical Properties |
| Melting point | 268-269°C | | Boiling point | 552.2±60.0 °C(Predicted) | | density | 1.572 | | storage temp. | Keep in dark place,Inert atmosphere,Room temperature | | solubility | insoluble in H2O; insoluble in EtOH; ≥12.80 mg/mL in DMSO | | pka | 3.88±0.10(Predicted) | | form | solid | | CAS DataBase Reference | 57381-26-7(CAS DataBase Reference) |
| | Irsogladine Usage And Synthesis |
| Definition | ChEBI: 6-(2,5-dichlorophenyl)-1,3,5-triazine-2,4-diamine is a dichlorobenzene. | | Biological Activity | irsogladine is a pde4 inhibitor and muscarinic acetylcholine receptor binder.irsogladine treatment (300 and 500 mg/kg/day) resulted in a dose-dependent reduction of angiogenesis in wild-type mice by 21 and 45.3% (p < 0.02, p < 0.001), in tpa-deficient mic |
| | Irsogladine Preparation Products And Raw materials |
|
